Aims and Methods: This study was carried out to clarify whether the urinary excretion of type IV collagen (u-IV collagen) detected by specific radioimmunoassay, can be used as an indicator for the progression of diabetic nephropathy. Results: u-IV collagen was higher in diabetic subjects with microalbuminuria and overt proteinuria than those with normoalbuminuria, IgA nephropathy, membranoproliferative glomerulonephritis, membranous nephropathy, or control normal subjects. u-IV collagen was positively correlated with serum and urinary β2-microglobulin and negatively with creatinine clearance only in diabetic patients, but not in patients with other glomerular diseases. The serum type IV collagen was not different between all the groups, and not correlated with its urinary excretion. In the advanced diabetic nephropathy, immunoreactive type IV collagen was detected in glomerular basement membrane (GBM), tubular basement membrane and Bowman’s capsule much more than that in the normal kidney. Conclusion: These findings indicated increased production and degeneration of type IV collagen in diabetic nephropathy. It is suggested that augmented turnover of type IV collagen in GBM and tubular basement membrane results in increased concentrations of free u-IV collagen. Therefore, measurement of u-IV collagen may be a useful, specific indicator of the progression of diabetic nephropathy.

Keywords:
Type IV collagen, Plasma, Urine, Diabetic nephropathy, Proteinuria
1.
Mogensen CE: Microalbuminuria as a predictor of clinical diabetic nephropathy. Kidney Int 1987;31:673–689.
2.
Viberti GC, Hill RD, Jarrett RJ, Argyropoulos A, Mahmud U, Keen H: Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet 1982;i:1430–1432.
3.
Nathan DM, Rosenbaum C, Protasowicki D: Single-void urine samples can be used to estimate quantitative microalbuminuria. Diabetes Care 1987;10:414–418.
4.
Watts NB: Albuminuria and diabetic nephropathy: An evolving history. Clin Chem 1991;37:2027.
5.
Redon J: Renal protection by antyhypertensive drugs: Insights from microalbuminuria studies. J Hypertens 1998;16:2091–2100.
6.
Mogensen CE: Diabetes mellitus and the kidney. Kidney Int 1982;21:673–675.
7.
Hayashi Y, Makino H, Ota Z: Serum and urinary concentrations of type IV collagen and laminin as a maker of microangiopathy in diabetes. Diabet Med 1992;9:366–370.
8.
Tomono S, Kawazu S, Kato N, Ohno T, Utsugi T, Murata K: Clinical implications of serum levels of basement membrane components in diabetic patients with and without albuminuria. J Diabetes Complications 1991;5:193–194.
9.
Matsumoto E: Foreknowledge of liver fibrosis. Development of immunoassay system for serum collagen peptides with monoclonal antibody. J Wakayama Med Soc 1988;39:87–106.
10.
Matsumoto E, Matsumoto G, Ooshima A, Kikuoka H, Bessho H, Miyamura K, Nanjo K: Serum type IV collagen concentrations in diabetic patients with microangiopathy as determined by enzyme immunoassay with monoclonal antibodies. Diabetes 1990;39:885–890.
11.
Obata K, Iwata K, Ichida T, Inoue K, Matsumoto E, Muragaki Y: One-step sandwich enzyme immunoassay for human type IV collagen using monoclonal antibodies. Clin Chem Acta 1989;181:293–304.
12.
Watanabe T, Negishi K, Katayama S, Ishii J, Kawazu S: Serum or urinary concentration of type IV collagen in diabetics. J Diabetes Complications 1991;5:191–192.
13.
Kieron L, Gerald D, Coles A, Williams JD: An Elisa for the detection of type IV collagen in human urine – Application to patients with glomerulonephritis. Kidney Int 1994;46:1431–1437.
14.
Kjellstrom T, Shiroishi K, Evrin PE: Urinary β2-microglobulin excretion among people exposed to cadmium in the general environment. An epidemiological study in co-operation between Japan and Sweden. Environ Res 1977;13:318–344.
15.
Mohan PS, Carter WG, Spiro RG: Occurrence of type IV collagen in extracellular matrix of renal glomeruli and its increase in diabetes. Diabetes 1990;39:31–37.
16.
Brownlee M, Spiro RG: Glomerular basement membrane metabolism in the diabetic rat. Diabetes 1979;28:121–125.
17.
Cohen MD, Surma ML, Wu VY: In vivo biosynthesis and turnover of glomerular basement membrane in diabetic rats. Am J Physiol 1982;242:385–389.
18.
Hasslacher CH, Kopischke HG, Bruklin E, Gechter F, Reichenbacher R: In vivo studies on basement membrane synthesis in diabetic and nondiabetic rats. Res Exp Med 1982;181:245–251.
19.
Brocks DG, Neubauer HP, Strecker H: Type IV collagen antigens in serum of diabetic rats: A marker for basement membrane collagen biosynthesis. Diabetologia 1985;28:928–932.
20.
Hogeman B, Voss B, Altenwerth FJ, Schneider M, Rauterberg J, Gerlach U: Concentrations of 7S collagen and laminin P1 in sera of patients with diabetes mellitus. Klin Wochenschr 1986;64:382–385.
21.
Hatashi Y, Makino H, Shikata K, Haramoto T: Increased concentrations of the basement membrane component type IV collagen in sera and urine of diabetics. J Diabetes Complications 1991;5:195–196.
22.
Torffvit O, Agardh CD, Aim P, Wieslander J: Urine and serum levels of the carboxy-terminal domain (NCl) of collagen IV in membranous glomerulonephritis and diabetic nephropathy. Nephron 1991;59:15–20.
23.
Haneda M, Kikkawa R, Horide N: Effect of aldose reductase inhibition on glucose-induced overproduction of type IV collagen in cultured glomerular mesangial cells; in Goto Y, Lee TH, Kaneko T, et al (eds): Prevention and Treatment of NIDDM. London, Smith-Gordon, 1992, pp 329–330.
24.
Bleyer A, Fumo P, Snipes ER: Polyol pathway mediates high glucose-induced collagen synthesis in proximal tubule. Kidney Int 1994;45:659–666.
25.
Shikata K, Makino H, Sugimoto H: Localization of advanced glycation end products in the kidney of experimental diabetic rats. J Diabetes Complications 1995;9:269–271.
26.
Iehara N, Takeoka H, Yamada Y, Kita T, Doi T: Advanced glycation end products modulate transcriptional regulation in mesangial cells. Kidney Int 1996;50:1166–1172.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.